Glens Falls Hospital

100 Park Street, Glens Falls, NY 12801 518.926.1000

Clinical Trials


P = Pharmacy
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center


Updated 6-16-15



N B51  

  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Pre-Activation Only) - On Hold

PUMA NER 1301          

  • (NALA) A Study of Neratinib Plus Capecitabine vs. Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Ca who Have Received >/= 2 Prior Her2-Directed Regimens in the Metastatic Setting

CTSU S1007  

  • A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with

              Recurrence Score (RS) of 25 or Less


CTSU A021202  

  • Prospective randomized phase II trial of Pazopanib vs. placebo in patients with progressive carcinoid tumors



C 80702  

  • A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

CTSU S0820  

  • A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Head and Neck


  • A Phase III Study of Postoperative Radiation Therapy (IMRT) =/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer


CTSU A041202   

  • A randomized Phase III Study of Bendamustine plus Rituximab vs Ibrutinib plus Rituximab vs Ibrutinib alone in Untreated Older Patients (0 65 years of age) with Chronic Lymphocytic Leukemia (CLL)


CTSU      E1912 

  • A Randomized Phase III Study of Ibrutinib(PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)


Lung: SCLC Limited:

C 30610

  • Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide



CTSU E1411  

  • Phase II 4-Arm Study In Patients 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV LR)



CTSU E2905  

  • Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

P Registry        

  • Celgene Corporation Connect MDS and AML: The Myelodysplastic  Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry



  •  A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma


CTSU S1216  

  • A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide inPatients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer




CTSU S0931  

  • EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study


Treatment Protocols

Glens Falls Hospital
Pruyn Pavilion
Research Office
Phone: (518) 926-6700
Fax: (518) 926-1954

Staff Directory


Robert W. Sponzo, M.D.
Aqeel Gillani, M.D.
John Stoutenburg, M.D.
Eric Pillemer, M.D.
Darci Gaiotti-Grubbs, M.D.
Mark Hoffman, M.D.

Alex Frank, M.D.


Clinical Research Support:

Beth Ann Brundage, RN, OCN
Nannette Oberhelman, CCRP
Jean VanAuken, RPA-C